Mary Gates

1.4k total citations
35 papers, 1000 citations indexed

About

Mary Gates is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Gates has authored 35 papers receiving a total of 1000 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Gates's work include Advanced Breast Cancer Therapies (10 papers), Neuroscience and Neuropharmacology Research (9 papers) and Estrogen and related hormone effects (7 papers). Mary Gates is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Neuroscience and Neuropharmacology Research (9 papers) and Estrogen and related hormone effects (7 papers). Mary Gates collaborates with scholars based in United States, United Kingdom and Spain. Mary Gates's co-authors include David Bleakman, Paul L. Ornstein, Ken H. Ho, Ann Marie L. Ogden, Peter Miu, David Lodge, Luna Musib, Zuner A. Bortolotto, Graham L. Collingridge and Bradford T. Brinton and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Mary Gates

35 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Gates United States	17	536	499	219	143	115	35	1000
Maura E. Charlton United States	13	792 1.5×	350 0.7×	157 0.7×	38 0.3×	71 0.6×	18	1.2k
J. Phillip Kennedy United States	21	1.4k 2.7×	683 1.4×	252 1.2×	83 0.6×	52 0.5×	32	1.8k
Qi-Huang Zheng United States	26	681 1.3×	327 0.7×	367 1.7×	188 1.3×	89 0.8×	93	1.9k
Zhengxin Cai United States	22	367 0.7×	361 0.7×	153 0.7×	76 0.5×	110 1.0×	63	1.2k
Rikki N. Waterhouse United States	20	872 1.6×	617 1.2×	133 0.6×	63 0.4×	35 0.3×	46	1.4k
Francesco Fiorentini Italy	19	495 0.9×	204 0.4×	231 1.1×	78 0.5×	50 0.4×	40	1.0k
Louise M. Perkins United States	19	792 1.5×	517 1.0×	98 0.4×	73 0.5×	31 0.3×	36	1.7k
Joanna M. Karasinska Canada	18	819 1.5×	416 0.8×	222 1.0×	75 0.5×	26 0.2×	44	1.5k
Mingzhang Gao United States	22	564 1.1×	183 0.4×	263 1.2×	125 0.9×	33 0.3×	89	1.6k
Zhenhua Shao China	19	766 1.4×	447 0.9×	69 0.3×	88 0.6×	72 0.6×	36	1.2k

Countries citing papers authored by Mary Gates

Since Specialization

Citations

This map shows the geographic impact of Mary Gates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Gates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Gates more than expected).

Fields of papers citing papers by Mary Gates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Gates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Gates. The network helps show where Mary Gates may publish in the future.

Co-authorship network of co-authors of Mary Gates

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Gates. A scholar is included among the top collaborators of Mary Gates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Gates. Mary Gates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yao, Xiaosai, Patrick Aouad, Lisa Crocker, et al.. (2025). ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nature Cancer. 6(2). 357–371. 3 indexed citations

Liang, Jackson J., Christy C. Ong, Jennifer M. Giltnane, et al.. (2024). Abstract PS17-01: Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Cancer Research. 84(9_Supplement). PS17–1. 1 indexed citations

Kshirsagar, Smita, Ya‐Chi Chen, Jiajie Yu, et al.. (2024). Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects. Drug Metabolism and Disposition. 52(8). 847–857. 2 indexed citations

Malhi, Vikram, Mary Gates, Lichuan Liu, et al.. (2023). Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer. Cancer Research Communications. 3(12). 2551–2559. 2 indexed citations

Chandarlapaty, Sarat, Maura N. Dickler, José Alejandro Pérez Fidalgo, et al.. (2023). An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 29(15). 2781–2790. 7 indexed citations

Ingalla, Ellen, Xiaosai Yao, Jennifer M. Giltnane, et al.. (2022). Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Science Translational Medicine. 14(663). eabo5959–eabo5959. 9 indexed citations

Bardia, Aditya, Ingrid A. Mayer, Eric P. Winer, et al.. (2022). The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 197(2). 319–331. 14 indexed citations

Daemen, Anneleen, Jill M. Spoerke, Wei Zhou, et al.. (2020). Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545. Cancer Research. 80(4_Supplement). P2–11. 1 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Eunice L. Kwak, et al.. (2019). Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Investigational New Drugs. 38(2). 419–432. 73 indexed citations

10.

Cheeti, Sravanthi, Hao Hou, Eric Nelson, et al.. (2018). Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects. Pharmaceutical Research. 35(12). 233–233. 6 indexed citations

11.

Liu, Lichuan, Sravanthi Cheeti, Kenta Yoshida, et al.. (2018). Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects. The Journal of Clinical Pharmacology. 58(11). 1427–1435. 29 indexed citations

12.

Takahashi, Ryan, Edna F. Choo, Jason Halladay, et al.. (2015). Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Drug Metabolism and Disposition. 44(1). 28–39. 37 indexed citations

13.

Choo, Edna F., Ryan Takahashi, Isabelle Rooney, et al.. (2013). Abstract B160: Assessing human absorption, metabolism, routes of excretion and the contribution of intestinal metabolism to the oral clearance of cobimetinib, a MEK inhibitor.. Molecular Cancer Therapeutics. 12(11_Supplement). B160–B160. 3 indexed citations

14.

Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2011). Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 4716–4716. 18 indexed citations

15.

Murray, Tracey K., Katherine Whalley, Mark Ward, et al.. (2003). LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 306(2). 752–762. 89 indexed citations

16.

Bleakman, David, Mary Gates, Alfred T. Ogden, & Marzena Maćkowiak. (2002). Kainate Receptor Agonists, Antagonists and Allosteric Modulators. Current Pharmaceutical Design. 8(10). 873–885. 31 indexed citations

17.

Gates, Mary, et al.. (2001). Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology. 40(8). 984–991. 31 indexed citations

18.

Ornstein, Paul L., Dennis M. Zimmerman, M. Brian Arnold, et al.. (2000). Biarylpropylsulfonamides as Novel, Potent Potentiators of 2-Amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic Acid (AMPA) Receptors. Journal of Medicinal Chemistry. 43(23). 4354–4358. 62 indexed citations

19.

Bortolotto, Zuner A., Vernon R. J. Clarke, Michael C. Parry, et al.. (1999). Kainate receptors are involved in synaptic plasticity. Nature. 402(6759). 297–301. 265 indexed citations

20.

Rasmussen, Kurt, et al.. (1997). The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neuroscience Letters. 222(1). 61–64. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact